Journal of Clinical Oncology, Vol 26, No 9 (March 20), 2008: pp. 1443-1451
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.0509
Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials
Gunnar Folprecht,
Matthew T. Seymour,
Leonard Saltz,
Jean-Yves Douillard,
Hartmut Hecker,
Richard J. Stephens,
Timothy S. Maughan,
Eric Van Cutsem,
Philippe Rougier,
Emmanuel Mitry,
Ute Schubert,
Claus-Henning Köhne
From the University Hospital Dresden; Medical School Hannover; and Klinikum Oldenburg, Germany; Cancer Research UK Clinical Centre, Cookridge Hospital, Leeds; Medical Research Council Clinical Trials Unit, London; and Velindre Hospital, Cardiff, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, NY; Centre R Gauducheau, St. Herblain; and Hôpital Ambroise Paré, Boulogne, France; and the University Hospital Gasthuisberg, Leuven, Belgium
Corresponding author: Gunnar Folprecht, MD, University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307; e-mail: gunnar.folprecht{at}uniklinikum-dresden.de
Purpose Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC).
Patients and Methods Combined analysis was carried out with source data from the fluorouracil (FU)/folinic acid (FA) and the irinotecan/FU/FA arms of four first-line, phase III trials of CRC to investigate the efficacy and safety of combination and monotherapy in elderly (age 70 years; n = 599) compared with younger (age < 70 years; n = 2,092) patients.
Results Response rates were improved with irinotecan-based combination therapy compared with FU/FA in patients both younger than 70 years and 70 years (46.6% v 29.0% P < .0001; and 50.5% v 30.3%, P < .0001, respectively). With irinotecan/FU/FA, progression-free survival was better for both younger (hazard ratio [HR], 0.77; 95% CI, 0.70 to 0.85; P < .0001) and elderly patients (HR, 0.75; 95% CI, 0.61 to 0.90; P = .0026). In younger patients, overall survival was improved with combination therapy (HR, 0.83; 95% CI, 0.75 to 0.92; P = .0003). The same trend was observed in elderly patients (HR, 0.87; 95% CI, 0.72 to 1.05; P = .15). There was no significant interaction between treatment arm and age in the regression analysis. The expected differences in toxicity between combination and monotherapy in elderly and younger patients were observed. A significant interaction between treatment and age (cutoff, 70 years) for vomiting and hepatotoxicity was not confirmed by analysis that used age as a continuous variable.
Conclusion Patients older than 70 years of age who were selected for inclusion in phase III trials derived similar benefits as younger patients from irinotecan-containing chemotherapy, and the risk of toxicity was similar.
Supported by Pfizer.
Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 2-5, 2007.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. S. Strimpakos, D. Cunningham, C. Mikropoulos, I. Petkar, Y. Barbachano, and I. Chau
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy
Ann. Onc.,
October 27, 2009;
(2009)
mdp449v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rosati, S. Cordio, R. Bordonaro, G. Caputo, G. Novello, G. Reggiardo, and L. Manzione
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
Ann. Onc.,
August 27, 2009;
(2009)
mdp359v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Sargent, C. H. Kohne, H. K. Sanoff, B. M. Bot, M. T. Seymour, A. de Gramont, R. Porschen, L. B. Saltz, P. Rougier, C. Tournigand, et al.
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
J. Clin. Oncol.,
April 20, 2009;
27(12):
1948 - 1955.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen
Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
J. Clin. Oncol.,
January 10, 2009;
27(2):
199 - 205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
Ann. Onc.,
January 1, 2009;
20(1):
5 - 16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Sanoff, D. J. Sargent, M. E. Campbell, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and R. M. Goldberg
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741
J. Clin. Oncol.,
December 10, 2008;
26(35):
5721 - 5727.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|